KPV vs Splenopentin

Overview

KPV and Splenopentin are both immune support peptides, but they differ in mechanism, dosing, and regulatory status.

This page compares KPV and Splenopentin across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.

Side-by-side comparison

Key differences

Primary use. KPV is categorised under Immune Support, while Splenopentin falls under Immune Support. Because they target a similar goal, they are common alternatives to weigh against each other.

Regulatory status. KPV: not FDA-approved; compounding permitted with a prescription as of April 2026. Splenopentin: not FDA-approved; treated as a research compound.

Dosing. KPV is typically dosed at 500-1000 mcg (daily). Splenopentin is typically dosed at 1-5 mg (as needed).

Can you stack them?

Some protocols combine peptides, but stacking KPV and Splenopentin has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.

Frequently asked questions

What is the difference between KPV and Splenopentin?

KPV and Splenopentin are both immune support peptides, but they differ in mechanism, dosing, and regulatory status. KPV is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Splenopentin is not FDA-approved; generally classified as a research compound.

What is KPV used for?

Anti-inflammatory immune peptide.

What is Splenopentin used for?

Spleen-derived immune peptide.

Can you take KPV and Splenopentin together?

Some users combine peptides within a single protocol, but stacking KPV and Splenopentin has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.

Is KPV or Splenopentin FDA-approved?

KPV is not FDA-approved; compounding permitted with a prescription (as of April 2026). Splenopentin is not FDA-approved; generally classified as a research compound.